The Effect of Commercial Sweetener Cipla on the Serum Lipid Profiles in Diabetes-Induced Rats

Deriving from sugar or sucrose, sucralose sweetener has no calories and is 600 times sweeter than sugar. Cipla as a commercial sweetener has different compounds, including lactose, L-leucine, cross, carmellose sodium, also creates a low calorie. In the present study the effect of Cipla on serum lipid profiles of diabetic and healthy rats was evaluated.
This study was conducted on 24 male Wistar rats weighing 230 ± 30 g that randomly divided into 4 equal groups: healthy control group, diabetic control group, healthy treatment group and the diabetic treatment group. Sucralose dosage in the present study was determined as daily 15 mg/kg for one month in healthy treatment group. The diabetic treatment group received that amount of sucralose by gavage. In order to induce diabetes in rats at 65 mg/kg dosage of streptozotocin was injected intraperitoneally and the rate of serum glucose was measured with a glucometer after 24 hours; so, the cases higher than 250 mg/dL were considered as diabetic rats. At the end of this process, blood samples were collected from tail vein of all rats. Following serum separation the serum lipid profiles (cholesterol, triglyceride, low-density lipoprotein [LDL], high-density lipoprotein [HDL]) were evaluated and analyzed using SPSS software (version 18).
In this study, although the lack of meaningful change in HDL and meaningful decrease of triglyceride and cholesterol was proved
It seems that the administration of the sweetener by diabetic and cardiovascular patients must be done with caution due to increasing and meaningful effect of Cipla on serum LDL.